Impact of nanotechnology in cancer: Emphasis on nanochemoprevention

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 591-605

  Siddiqui, Imtiaz A ^a   Adhami, Vaqar M ^a   Chamcheu, Christopher Jean ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cancer; Nanochemoprevention; Nanotechnology

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; CARBON NANOTUBE; CURCUMIN; CYTARABINE; DAUNORUBICIN; DENDRIMER; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; FULLERENE DERIVATIVE; LIPOSOME; MEGESTROL ACETATE; NANOCANTILEVER; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; POLYPHENOL; QUANTUM DOT; QUERCETIN; RESVERATROL; STILMALMAR; TANNIN; THEAFLAVIN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; VIVAGEL; ZINOSTATIN; CISPLATIN; FLAVONOID; NATURAL PRODUCT; PIPERINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AIRWAY OBSTRUCTION; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RESEARCH; CANCER THERAPY; CHEMICAL MODIFICATION; DIAGNOSTIC IMAGING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FLUSHING; FOLLICULAR LYMPHOMA; HUMAN; HYPERTENSION; HYPOTENSION; KAPOSI SARCOMA; LEUKEMIA; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MICELLE; MICROANALYSIS; NANOCHEMOPREVENTION; NANOMEDICINE; NANOTECHNOLOGY; NANOTOXICOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RESPIRATORY TRACT DISEASE; RESTENOSIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; NANOENCAPSULATION; NANOFABRICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; SKIN MANIFESTATION; ANIMAL; CHEMISTRY; METHODOLOGY; NEOPLASM;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; HUMANS; NANOMEDICINE; NEOPLASMS;

EID: 84856667905     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257-288.
2. Niemeyer CM. Semi-synthetic nucleic acid-protein conjugates: applications in life sciences and nanobiotechnology. J Biotechnol. 2001; 82(1):47-66.
3. Nishiyama N. Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol. 2007;2(4):203-204.
4. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-171.
5. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006;107(3):459-466.
6. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58(2):97-110.
7. McNeil SE. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(3):264-271.
8. Freitas RA. What is nanomedicine? Nanomedicine. 2005;1(1):2-9.
9. Freitas RA. Current status of nanomedicine and medical nanorobotics. J Comput Theor Nanos. 2005;2(1):1-25.
10. Torchilin V. Antibody-modifed liposomes for cancer chemotherapy. Expert Opin Drug Deliv. 2008;5(9):1003-1025.
11. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007;59(8):718-728.
12. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112-1120.
13. Barreto JA, O'Malley W, Kubeil M, Graham B, Stephan H, Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater. 2011;23(12):H18-H40.
14. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37(7):870-877.
15. Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs. 2000;11(2):123-127.
16. Forssen EA, Male-Brune R, Adler-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (Dauno-Xome) within tumor tissue. Cancer Res. 1996;56(9):2066-2075.
17. Guaglianone P, Chan K, DelaFlor-Weiss E, et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs. 1994;12(2):103-110.
18. Jaeckle KA, Batchelor T, O'Day SJ, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002;57(3): 231-239.
19. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5(11):3394-3402.
20. Vincristine liposomal - INEX: lipid-encapsulated vincristine, Onco TCS, transmembrane carrier system - vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI. Drugs R D. 2004;5(2): 119-123.
21. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma. 2005; 46(6):795-802.
22. Charrois GJ, Allen TM. Drug release rate infuences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta. 2004;1663(1-2):167-177.
23. Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev. 2004;56(7):947-965.
24. Leamon CP, Cooper SR, Hardee GE. Folate-liposome-mediated anti-sense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem. 2003;14(4):738-747.
25. Orive G, Gascon AR, Hernandez RM, Dominguez-Gil A, Pedraz JL. Techniques: new approaches to the delivery of biopharmaceuticals. Trends Pharmacol Sci. 2004;25(7):382-387.
26. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today. September 29, 2011. [Epub ahead of print.]
27. Chan A, Shih V, Tham Chee K. Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures. J Oncol Pharm Pract. 2007;13(2):105-107.
28. Szebeni J. Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins. Curr Drug Deliv. 2005;2(4):443-449.
29. Veal GJ, Griffn MJ, Price E, et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer. 2001;84(8): 1029-1035.
30. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006;95(7):822-828.
31. Steele JP, O'Doherty CA, Shamash J, et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol. 2001; 12(4):497-499.
32. Xing Y, Smith AM, Agrawal A, Ruan G, Nie S. Molecular profling of single cancer cells and clinical tissue specimens with semiconductor quantum dots. Int J Nanomedicine. 2006;1(4):473-481.
33. Seydel C. Quantum dots get wet. Science. 2003;300(5616):80-81.
34. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science. 1998;281(5385):2013-2016.
35. Pinaud F, Michalet X, Bentolila LA, et al. Advances in fuorescence imaging with quantum dot bio-probes. Biomaterials. 2006;27(9): 1679-1687.
36. Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol. 2005;16(1):63-72.
37. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307(5709):538-544.
38. Alivisatos P. The use of nanocrystals in biological detection. Nat Biotechnol. 2004;22(1):47-52.
39. Shiohara A, Hoshino A, Hanaki K, Suzuki K, Yamamoto K. On the cyto-toxicity caused by quantum dots. Microbiol Immunol. 2004;48(9): 669-675.
40. Lovric J, Bazzi HS, Cuie Y, Fortin GR, Winnik FM, Maysinger D. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med (Berl). 2005;83(5): 377-385.
41. Hoshino A, Manabe N, Fujioka K, Suzuki K, Yasuhara M, Yamamoto K. Use of fuorescent quantum dot bioconjugates for cellular imaging of immune cells, cell organelle labeling, and nanomedicine: surface modifcation regulates biological function, including cytotoxicity. J Artif Organs. 2007;10(3):149-157.
42. Choi AO, Cho SJ, Desbarats J, Lovric J, Maysinger D. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J Nanobiotechnol. 2007;5:1.
43. Gao X, Chung LW, Nie S. Quantum dots for in vivo molecular and cellular imaging. Methods Mol Biol. 2007;374:135-145.
44. Smith AM, Ruan G, Rhyner MN, Nie S. Engineering luminescent quantum dots for in vivo molecular and cellular imaging. Ann Biomed Eng. 2006;34(1):3-14.
45. Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science. 2002;298(5599):1759-1762.
46. Rawat M, Singh D, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull. 2006;29(9):1790-1798.
47. Hamaguchi T, Matsumura Y, Suzuki M, et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92(7):1240-1246.
48. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. Adv Drug Deliv Rev. 2002;54(2): 169-190.
49. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor effcacy. Bioconjug Chem. 2005;16(1):122-130.
50. Nakanishi T, Fukushima S, Okamoto K, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release. 2001;74(1-3):295-302.
51. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A. 2003;100(10):6039-6044.
52. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: a novel controlled delivery vehicle for cancer therapy. Nanomedicine (Lond). 2010;5(3):433-449.
53. Wu G, Datar RH, Hansen KM, Thundat T, Cote RJ, Majumdar A. Bioassay of prostate-specifc antigen (PSA) using microcantilevers. Nat Biotechnol. 2001;19(9):856-860.
54. Tekade RK, Kumar P V, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev. 2009;109(1):49-87.
55. Svenson S, Tomalia DA. Dendrimers in biomedical applications - refections on the feld. Adv Drug Deliv Rev. 2005;57(15):2106-2129.
56. Tomalia DA. Supramolecular chemistry: fuorine makes a difference. Nat Mater. 2003;2(11):711-712.
57. Choi Y, Thomas T, Kotlyar A, Islam MT, Baker JR. Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specifc targeting. Chem Biol. 2005;12(1): 35-43.
58. Xu H, Regino CA, Koyama Y, et al. Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fuorescence imaging. Bioconjug Chem. 2007;18(5):1474-1482.
59. Kobayashi H, Brechbiel MW. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol Imaging. 2003; 2(1):1-10.
60. Jiang YH, Emau P, Cairns JS, et al. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses. 2005;21(3):207-213.
61. Grodzinski P, Silver M, Molnar LK. Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn. 2006;6(3): 307-318.
62. Nune SK, Gunda P, Thallapally PK, Lin YY, Forrest ML, Berkland CJ. Nanoparticles for biomedical imaging. Expert Opin Drug Deliv. 2009; 6(11):1175-1194.
63. Bianco A, Kostarelos K, Partidos CD, Prato M. Biomedical applications of functionalised carbon nanotubes. Chem Commun (Camb). 2005;5: 571-577.
64. Bachilo SM, Strano MS, Kittrell C, Hauge RH, Smalley RE, Weisman RB. Structure-assigned optical spectra of single-walled carbon nanotubes. Science. 2002;298(5602):2361-2366.
65. Pastorin G, Wu W, Wieckowski S, et al. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb). 2006;11:1182-1184.
66. Radomski A, Jurasz P, Alonso-Escolano D, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005; 146(6):882-893.
67. Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci. 2004;77(1):117-125.
68. Muller J, Huaux F, Moreau N, et al. Respiratory toxicity of multi-wall carbon nanotubes. Toxicol Appl Pharmacol. 2005;207(3):221-231.
69. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133-149.
70. Yin JJ, Lao F, Meng J, et al. Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger. Mol Pharmacol. 2008;74(4):1132-1140.
71. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today. 2010;15(19-20): 842-850.
72. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263(5153):1600-1603.
73. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem. 2006;384(3):620-630.
74. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Na nocarriers as an emerging platform for cancer therapy. Nat N anotechnol. 2007;2(12):751-760.
75. Kawasaki ES, Player A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine. 2005;1(2):101-109.
76. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;16(2-3):215-233.
77. Deng C, Tian H, Zhang P, Sun J, Chen X, Jing X. Synthesis and characterization of RGD peptide grafted poly(ethylene glycol)-b-poly(L-lactide)-b-poly(L-glutamic acid) triblock copolymer. Biomacromolecules. 2006;7(2):590-596.
78. Mosqueira VC, Legrand P, Morgat JL, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res. 2001;18(10):1411-1419.
79. Stolnik S, Dunn SE, Garnett MC, et al. Surface modifcation of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res. 1994;11(12):1800-1808.
80. Siddiqui IA, Adhami VM, Bharali DJ, et al. Introducing nanochemo-prevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009;69(5):1712-1716.
81. Shutava TG, Balkundi SS, Vangala P, et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano. 2009;3(7):1877-1885.
82. Shutava TG, Balkundi SS, Lvov YM. Epigallocatechin gallate/ gelatin layer-by-layer assembled flms and microcapsules. J Colloid Interface Sci. 2009;330(2):276-283.
83. Barras A, Mezzetti A, Richard A, et al. Formulation and characterization of polyphenol-loaded lipid nanocapsules. Int J Pharm. 2009;379(2): 270-277.
84. Zu YG, Yuan S, Zhao XH, Zhang Y, Zhang XN, Jiang R. Preparation, activity and targeting ability evaluation in vitro on folate mediated epigallocatechin-3-gallate albumin nanoparticles. Yao Xue Xue Bao. 2009;44(5):525-531. Chinese.
85. Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci. 2010;41(2):219-225.
86. Han DW, Lee JJ, Jung DY, Park JC, Hyon SH. Development of epi-gallocatechin gallate-eluting polymeric stent and its physicochemical, biomechanical and biological evaluations. Biomed Mater. 2009;4(4): 44104.
87. Italia JL, Datta P, Ankola DD, Kumar MNVR. Nanoparticles enhance per oral bioavailability of poorly available molecules: epigallocatechin gallate nanoparticles ameliorates cyclosporine induced nephrotoxicity in rats at three times lower dose than oral solution. J Biomed Nanotechnol. 2008;4:304-312.
88. Rocha S, Generalov R, Pereira Mdo C, Peres I, Juzenas P, Coelho MA. Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention. Nanomedicine (Lond). 2011;6(1): 79-87.
89. Singh M, Bhatnagar P, Srivastava AK, Kumar P, Shukla Y, Gupta KC. Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J Biomed Nanotechnol. 2011;7(1):202.
90. Hsieh DS, Wang H, Tan SW, et al. The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials. 2011;32(30):7633-7640.
91. Aziz MH, Reagan-Shaw S, Wu J, Longley BJ, Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J. 2005;19(9):1193-1195.
92. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol. 2003;23(1):17-28.
93. Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci. 2002;957:210-229.
94. Yao Q, Hou SX, He WL, et al. Study on the preparation of resveratrol chitosan nanoparticles with free amino groups on the surface. Zhongguo Zhong Yao Za Zhi. 2006;31(3):205-208. Chinese.
95. Shao J, Li X, Lu X, et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces. 2009;72(1):40-47.
96. Lu X, Ji C, Xu H, et al. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int J Pharm. 2009;375(1-2): 89-96.
97. Narayanan NK, Nargi D, Randolph C, Narayanan BA. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer. 2009; 125(1):1-8.
98. Kobierski S, Ofori-Kwakye K, Muller RH, Keck CM. Resveratrol nanosuspensions for dermal application - production, characterization, and physical stability. Pharmazie. 2009;64(11):741-747.
99. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm. 2010;390(1):61-69.
100. Yadav VR, Aggarwal BB. Curcumin: A component of the golden spice, targets multiple angiogenic pathways. Cancer Biol Ther. 2011;11(2): 236-241.
101. Tonnesen HH. Solubility, chemical and photochemical stability of curcumin in surfactant solutions. Studies of curcumin and curcuminoids, XXVIII. Pharmazie. 2002;57(12):820-824.
102. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm. 2007;337(1-2):299-306.
103. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A. P olymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology. 2007;5:3.
104. Sahu A, Bora U, Kasoju N, Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater. 2008;4(6):1752-1761.
105. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol. 2008;32(5):1119-1123.
106. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine. 2010;6(1):153-160.
107. Merrell JG, McLaughlin SW, Tie L, Laurencin CT, Chen AF, Nair LS. Curcumin loaded poly(epsilon-caprolactone) nanofbers: diabetic wound dressing with antioxidant and anti-infammatory properties. Clin Exp Pharmacol Physiol. 2009;36(12):1149-1156.
108. Li J, Wang Y, Yang C, et al. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol. 2009;76(1):81-90.
109. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci. 2009;37(3-4):223-230.
110. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine. 2010;6(1):153-160.
111. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010;79(3):330-338.
112. Mukerjee A, Vishwanatha JK. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res. 2009;29(10):3867-3875.
113. Onoue S, Takahashi H, Kawabata Y, et al. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci. 2010;99(4): 1871-1881.
114. Sou K, Oyajobi B, Goins B, Phillips WT, Tsuchida E. Characterization and cytotoxicity of self-organized assemblies of curcumin and amphiphatic poly(ethylene glycol). J Biomed Nanotechnol. 2009; 5(2):202-208.
115. Prajakta D, Ratnesh J, Chandan K, et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J Biomed Nanotechnol. 2009;5(5):445-455.
116. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci. 2010;351(1): 19-29.
117. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010;3:11.
118. Rozzi A, Nardoni C, Corona M, Restuccia MR, Falbo T, Lanzetta G. Weekly regimen of paclitaxel and carboplatin as frst-line chemotherapy in elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results of a Phase II study. J Chemother. 2011; 22(6):419-423.
119. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of infammatory pathways by nutraceuticals. Cancer Metastasis Rev. 2010;29(3):405-434.
120. Wu YY, Chang JY, Chao TY. Paclitaxel and carboplatin-induced complete remission in peritoneal carcinomatosis of unknown origin: a report of two cases and review of the literature. Tumori. 2010; 96(2):336-339.
121. George J, Banik NL, Ray SK. Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth. J Cell Mol Med. 2009;13(10): 4205-4218.
122. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release. 2002;83(2):273-286.
123. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11(4):413-424.
124. Onyuksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009;274(2):327-330.
125. Sahoo SK, Ma W, Labhasetwar V. Effcacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004;112(2):335-340.
126. Van S, Das SK, Wang X, et al. Synthesis, characterization, and biological evaluation of poly(L-gamma-glutamyl-glutamine)-paclitaxel nanoconjugate. Int J Nanomedicine. 2010;5:825-837.
127. Lee AL, Wang Y, Pervaiz S, Fan W, Yang YY. Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. Macromol Biosci. 2011;11(2):296-2307.
128. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nano-particles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine. 2009;4(1):1-7.
129. Bharali DJ, Lucey DW, Jayakumar H, Pudavar HE, Prasad PN. Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. J Am Chem Soc. 2005; 127(32):11364-11371.
130. Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60(15): 1627-1637.
131. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-6320.
132. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
133. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769.
134. Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle. 2005;4(2):269-278.